3//SEC Filing
ARCH Venture Fund VIII, L.P. 3
Accession 0000899243-20-028091
CIK 0001659352other
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 9:23 PM ET
Size
28.5 KB
Accession
0000899243-20-028091
Insider Transaction Report
Form 3
ARCH Venture Fund VIII, L.P.
10% Owner
Holdings
- (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (420,784 underlying) - 63,963(indirect: See Footnote)
Common Stock
- (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (1,784,572 underlying) - (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (831,521 underlying) - (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (327,277 underlying) - (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (191,992 underlying)
Footnotes (5)
- [F1]Shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F2]Each share of Series A Preferred Stock is convertible into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F3]Each share of Series B Preferred Stock is convertible into Common Stock on an approximately 1-for-7.1295 basis into the aggregate number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F4]Each share of Series C Preferred Stock is convertible into Common Stock on an approximately 1-for-6.8758 basis into the aggregate number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
- [F5]Shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Issuer
Codiak BioSciences, Inc.
CIK 0001659352
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001605598
Filing Metadata
- Form type
- 3
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 9:23 PM ET
- Size
- 28.5 KB